Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL249073 | 0.84 | CYP1A2 (0.31) | — | |
| SCHEMBL2318595 | 0.76 | CYP1A2 (0.32) | — | |
| SCHEMBL4304637 | 0.76 | — | — | |
| SCHEMBL2411016 | 0.75 | CYP1A2 (0.32) | — | |
| SCHEMBL2256346 | 0.74 | ALDH1A1 (0.55) | — | |
| SCHEMBL386156 | 0.74 | CYP1A2 (0.55) | — | |
| SCHEMBL20560732 | 0.74 | HPRT1 (0.31) | — | |
| SCHEMBL10418671 | 0.74 | HPRT1 (0.31) | — | |
| SCHEMBL29069161 | 0.74 | HSD17B1 (0.31) | — | |
| SCHEMBL220753 | 0.73 | PARP1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3625223-B1 | PYRIMIDINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-08-11 | — | — | EP | claimed |
| US-20200108068-A1 | PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2020-04-09 | — | — | US | claimed |
| EP-3625223-A1 | PYRIMIDINE DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | claimed |
| CN-110621667-A | Pyrimidine derivatives | 爱杜西亚药品有限公司 | 2019-12-27 | — | — | CN | claimed |
| EP-3558969-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2019-10-30 | — | — | EP | claimed |
| WO-2018210992-A1 | PYRIMIDINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | claimed |
| WO-2018119036-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2018-06-28 | — | — | WO | claimed |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN-CILAG (FR) | 2018-06-21 | — | — | US | claimed |
| EP-2576543-B1 | PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2016-12-21 | — | — | EP | claimed |
| US-9505753-B2 | Inhibitors of D-amino acid oxidase | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-11-29 | — | — | US | claimed |
| US-9181195-B2 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-11-10 | — | — | US | claimed |
| US-8927570-B2 | 1-naphthyl-or 1-dihydroacenaphthenyl-pyrido[B]indoles and uses thereof in treating cancers | BUOLAMWINI JOHN K (US) | 2015-01-06 | — | — | US | claimed |
| US-20130158029-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-06-20 | — | — | US | claimed |
| WO-2013074871-A2 | HUMANIN ANALOGS | COHBAR, INC. (US) | 2013-05-23 | — | — | WO | claimed |
| US-20130131070-A1 | 1-Aryl or 1- Heteroaryl-Pyrido(B)indoles and Uses Thereof | BUOLAMWINI JOHN K (US) | 2013-05-23 | — | — | US | claimed |
| EP-2576543-A1 | PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS | Laboratorios del Dr. Esteve S.A. (ES) | 2013-04-10 | — | — | EP | claimed |
| CN-103003267-A | Sigma receptor inhibitors | ESTEVE LABOR DR | 2013-03-27 | — | — | CN | claimed |
| EP-2395003-A1 | Pyrazole compounds as sigma receptor inhibitors | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-12-14 | — | — | EP | claimed |
| WO-2011147910-A1 | PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-12-01 | — | — | WO | claimed |
| US-4939148-A | Amine derivatives, processes for their production and their use | SANDOZ, LTD. (CH) | 1990-07-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158029-A1 | SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRL1 | GPR84 141/4885CES2 373/4885CES1 479/4885 |
| US-20200108068-A1 | PYRIMIDINE DERIVATIVES | PTGER1, PTGER4, PTGER2 | GPR84 230/4885CES2 3981/4885CES1 1736/4885 |
| US-20130131070-A1 | 1-Aryl or 1- Heteroaryl-Pyrido(B)indoles and Uses Thereof | HRH3, HRH4, CNR1 | GPR84 1282/4885CES2 1873/4885CES1 464/4885 |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | MALT1, PPP3R1, SQSTM1 | GPR84 3882/4885CES2 3604/4885CES1 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.